PitchBook clients can access the full report and Excel data pack via the Research Center on the PitchBook Platform.
Selective recovery: Asset-centric NewCos and strategic M&A define biopharma in Q4 2025
Biopharma VC continued a modest recovery in 2025, with deal value rising for the second straight year to $33.8 billion—even as investors remained highly selective. Capital concentrated into fewer, larger financings, favoring de-risked assets, late-stage NewCos, and platforms that address clearly defined biological bottlenecks. Q4 activity highlighted this shift, with megadeals clustering around asset-centric companies built for execution, alongside continued support for differentiated technologies such as next-generation ADCs, RNA delivery beyond the liver, and AI-enabled drug discovery.
Exit markets also showed improving momentum late in the year. Strategic M&A drove most of the largest Q4 exits as Big Pharma looked to offset looming patent cliffs, while IPO activity reopened unevenly across global markets. Hong Kong emerged as the most active listing venue, led by Insilico Medicine’s offering, while the US showed early signs of selective reopening. Together, these trends pointed to a disciplined—but durable—recovery heading into 2026, supported by improving exit pathways, sustained interest in AI-native biopharma, and continued investor appetite for execution-ready assets with clearer paths to returns.
Table of contents
| Biopharma landscape | 3 |
| Quarterly analysis | 4 |
| Key takeaways | 4 |
| VC activity | 4 |
| Notable VC deals | 6 |
| VC exit activity | 7 |
| AI themes | 8 |
| Other notable events | 9 |
| Conclusions | 9 |
| Biopharma VC deal summary | 25 |
Early-stage biopharma VC funding is being redefined as capital flows into fewer but larger rounds, with investors backing companies with more developed programs than “early stage” once implied.
